AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7971302
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (control)
Trial: 29664001
Drug: Mild hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypothermia treatment
Trial: 27484576
Drug: Intravenous glutamate
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous glutamate
Trial: 20386120
Drug: beta-alanine (BA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-alanine (BA, n = 14) 1.5 g + 15 g dextrose powder
Trial: 20386120
Drug: placebo (PL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (PL, n = 19) 16.5 g dextrose powder
Trial: 15955378
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine)
Trial: 12461343
Drug: Hylan B
RxNorm normalized name: hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan B gel
Trial: 10608577
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with sex steroids
Trial: 1646341
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg AG-1749 (lansoprazole)
Trial: 1646341
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg AG-1749 (lansoprazole)
Trial: 7032303
Drug: 3% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% acyclovir ointment five times daily for 14 days
Trial: 7032303
Drug: 3% vidarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% vidarabine ointment five times daily for 14 days
Trial: 30807853
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg daily) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Trial: 30807853
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral vitamin B12 tablets) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Trial: 29902295
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg/d) with ERBB mutation-positive disease
Trial: 29902295
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg/d) without ERBB mutation-positive disease
Trial: 27081739
Drug: Standard-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose tacrolimus (TAC)
Trial: 27081739
Drug: Everolimus plus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus plus reduced-dose tacrolimus (EVR + rTAC) in hepatitis-C sub-population
Trial: 22578752
Drug: Early oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oxytocin augmentation
Trial: 22578752
Drug: Postponed oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postponed oxytocin augmentation
Trial: 22578752
Drug: Both early
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both early and postponed oxytocin treatment groups
Trial: 18931201
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (approximately 6 g)
Trial: 10951891
Drug: nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nedocromil sodium 2% ophthalmic solution b.i.d.
Trial: 29954814
Drug: Standard-of-care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care chemotherapy (SOC)
Trial: 27254033
Drug: Bivalent oral
RxNorm normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent oral poliovirus vaccine
Trial: 25242048
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1000 mg daily) plus prednisone (5 mg twice a day)
Trial: 17687266
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment in bipolar patients
Trial: 12429243
Drug: Povidone-iodine 1.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine 1.25% ophthalmic solution, one drop 4 times daily in the affected eye.
Trial: 12429243
Drug: Neomycin-polymyxin-B-gramicidin ophthalmic
RxNorm normalized name: gramicidin / neomycin / polymyxin B Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin-polymyxin-B-gramicidin ophthalmic solution, one drop 4 times daily in the affected eye.
Trial: 12429243
Drug: Povidone-iodine 1.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine 1.25% ophthalmic solution and Neomycin-polymyxin-B-gramicidin
Trial: 22492518
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg, twice daily
Trial: 22492518
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg, twice daily
Trial: 20424424
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (50 microg/kg/day, n = 45)
Trial: 18586683
Drug: Vitamin K-antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K-antagonist alone
Trial: 16103383
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.5 mg) and sufentanil (5 microg)
Trial: 16103383
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural infusion of bupivacaine (0.25%) and fentanyl (2 microg/mL)
Trial: 10443606
Drug: 125 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/kg epsilon‐ACA followed by an infusion of 12.5 mg x kg(‐1) x h(‐1)
Trial: 7821198
Drug: Segmental allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segmental allergen provocation with 250 PNU in 5 ml 0.9% NaCl solution of birch or grass pollen
Trial: 6761088
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg clotrimazole vaginal tablets
Trial: 6761088
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg econazole vaginal ovules
Trial: 30006020
Drug: Second-generation electronic
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation electronic cigarettes (ECIGs) with 0 or 18 ng/ml nicotine, used ad libitum for two weeks.
Trial: 20518225
Drug: Weekly massage
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly massage treatments at work for a four week period
Trial: 12557618
Drug: Co-induction group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-induction group (midazolam 3 mg, alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Trial: 12557618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Trial: 9829442
Drug: Percutaneous 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous 17beta-estradiol gel (1.5 mg/d)
Trial: 9829442
Drug: Transdermal 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta-estradiol patch (50 microg/d)
Trial: 9829442
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol valerate (2 mg/d)
Trial: 7911863
Drug: Metoprolol preadsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol preadsorbed onto activated charcoal (100 mg metoprolol tartrate/120 mg charcoal)
Trial: 7911863
Drug: Pindolol preadsorbed
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol preadsorbed onto activated charcoal (10 mg pindolol/20 mg charcoal)
Trial: 7911863
Drug: Metoprolol control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol control (capsule containing the drug only)
Trial: 7911863
Drug: Pindolol control
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol control (conventional tablet)
Trial: 2686934
Drug: Atropine plus
RxNorm normalized name: atropine / edrophonium Injection [Enlon-Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine plus succinylcholine (2 mg/kg)
Trial: 31392517
Drug: Chloroquine 500
RxNorm normalized name: chloroquine 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 500 mg daily for 2-6 weeks
Trial: 26227099
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa 150 μg (therapeutic dose)
Trial: 26227099
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa 240 μg (supratherapeutic dose)
Trial: 22403966
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg before surgery, then twice a day for 2 days
Trial: 15089065
Drug: Ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.15 mg/kg, n = 39)
Trial: 15089065
Drug: Ondansetron plus
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron plus dexamethasone (0.15 mg/kg ondansetron and 0.2 mg/kg dexamethasone, n = 30)
Trial: 10891023
Drug: Psychological questionnaires
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological questionnaires administered at baseline to parents and participants
Trial: 23949586
Drug: Vaginal suppository
RxNorm normalized name: Vaginal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) twice a day for 7 days
Trial: 23949586
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole 2 g single dose
Trial: 23949586
Drug: Vaginal suppository
RxNorm normalized name: Vaginal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) once a day for 7 days
Trial: 20075691
Drug: Cool gel
RxNorm normalized name: Menthol 2% Topical application Gel/Jelly [COOL GEL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cool gel wrap and leg elevation intervention
Trial: 17974502
Drug: Home blood
RxNorm normalized name: LifeSource Aneroid Home Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home blood pressure monitoring receipt and proficiency training on its use and the Group Health secure patient website (with secure e-mail access to their healthcare provider, access to a shared medical record, prescription refill and other services)
Trial: 15915035
Drug: Nefopam and
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam and Ketoprofen combination
Trial: 13130407
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (300 mg tablet once daily)
Trial: 10995520
Drug: Spironolactone added
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone added to standard multidrug therapy (ACE inhibitor and loop diuretic)
Trial: 10995520
Drug: Standard multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multidrug therapy (ACE inhibitor and loop diuretic)
Trial: 8637535
Drug: Testosterone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (600 mg of testosterone enanthate weekly for 10 weeks)
Trial: 1323624
Drug: Foscarnet therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet therapy (60 mg/kg every 8 h)
Trial: 30545387
Drug: Crossover group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover group (after 3 months of exercise therapy)
Trial: 30545387
Drug: BMC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMC treatment (after crossover)
Trial: 26750669
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 mcg/kg, iv) + midazolam (0.5 mg, iv)
Trial: 26750669
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg, iv) + midazolam (0.5 mg, iv)
Trial: 18614450
Drug: CBT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBT intervention (6-month weekly group and individual sessions)
Trial: 12625572
Drug: Defibrinogenation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrinogenation therapy (BX group)
Trial: 12625572
Drug: High-dose steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroid therapy (PSL group)
Trial: 10587327
Drug: Rifabutin 300
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg and isoniazid 750 mg twice weekly for 3 months (group A)
Trial: 10587327
Drug: Rifabutin 600
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 600 mg and isoniazid 750 mg twice weekly for 3 months (group B)
Trial: 10587327
Drug: Isoniazid 300
RxNorm normalized name: isoniazid 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 300 mg/day for 6 months (group C)
Trial: 8100913
Drug: Intravenous CGRP
RxNorm normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CGRP (0.6 micrograms/min for 3 h per day on 5 days)
Trial: 8100913
Drug: Intravenous CGRP
RxNorm normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CGRP
Trial: 3734845
Drug: Human lymphoblastoid
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human lymphoblastoid interferon (HLBI) 3 MU/m2, i.m. (weekly maintenance)
Trial: 27653164
Drug: Zofenopril 30
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30 mg plus Hydrochlorothiazide 12.5 mg
Trial: 27653164
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg plus Hydrochlorothiazide 12.5 mg
Trial: 23242248
Drug: Innovator cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovator cisplatin formulation
Trial: 23242248
Drug: Generic cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic cisplatin formulation
Trial: 9817475
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg test dose, followed by 12.5 mg 3 times daily for 24 hours and 25 mg 3 times daily for the next 24 hours)
Trial: 9817475
Drug: Losartan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (25 mg/day increased to 50 mg after 24 hours)
Trial: 9817475
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus Furosemide (40 mg in the morning)
Trial: 8291700
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg long‐acting orally 12 h before surgery and 10 mg sublingually 1.5 h before surgery
Trial: 8291700
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg sublingually just before induction of anesthesia
Trial: 2557183
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg orally, 10 and 2 hours before dosing)
Trial: 2557183
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (120 cc)
Trial: 21984584
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion during hypoglycemia
Trial: 21984584
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion during euglycemia
Trial: 21984584
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion during hyperglycemia
Trial: 21984584
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during hypoglycemia
Trial: 21984584
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during euglycemia
Trial: 21984584
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during hyperglycemia
Trial: 16501248
Drug: EHMT1-g-9441a SNP
RxNorm normalized name: ALCOHOL 350 g in 100 mL TOPICAL GEL [SNP MY FIRST HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHMT1-g-9441a SNP
Trial: 9362356
Drug: Intra-arterial injection
RxNorm normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial injection of 131I-labeled Lipiodol (60 mCi; 2.2 GBq) (n = 73)
Trial: 9362356
Drug: Chemoembolization (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization (70 mg cisplatin) (n = 69)
Trial: 9362356
Drug: Intra-arterial injection
RxNorm normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial injection of 131I-labeled Lipiodol (n = 73)
Trial: 3511878
Drug: Desipramine hydrochloride
RxNorm normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine hydrochloride treatment
Trial: 3511878
Drug: Desipramine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine therapy after crossover from placebo
Trial: 22735175
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavior therapy (G-CBT) plus pharmacotherapy
Trial: 22735175
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; only pharmacotherapy)
Trial: 16135476
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for chronic insomnia
Trial: 7560222
Drug: Solution A
RxNorm normalized name: I.V. SOLUTION ADDITIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution A (0.06% triclosan + 2% tween 80)
Trial: 7560222
Drug: Solution B
RxNorm normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution B (0.06% triclosan + 0.25% sodium lauryl sulphate)
Trial: 31644515
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (DEX) 1.5 μg/kg
Trial: 31644515
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline (Placebo)
Trial: 23565740
Drug: Glimepiride (individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (individually titrated up to 4 mg)
Trial: 23565740
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Vildagliptin and Glimepiride)
Trial: 21098799
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg bolus, 0.5 mg/kg top-up if needed) with fentanyl (3 μg/kg bolus)
Trial: 21098799
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg bolus, 0.1 mg/kg top-up if needed) with fentanyl (3 μg/kg bolus)
Trial: 9257379
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream 0.025% applied nightly
Trial: 30883516
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) 5 mg/kg every 4 weeks for up to 20 weeks
Trial: 29877964
Drug: ECT plus
RxNorm normalized name: Protect Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT plus antipsychotic drugs (APD)
Trial: 29877964
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drugs (APD) only
Trial: 24930728
Drug: Losmapimod (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod (7.5 mg or 15.0 mg loading dose followed by 7.5 mg twice daily)